Andrew Sulaiman

2.1k citations
18 papers · 1.7k indexed · 1 hit paper · h-index 12

Andrew Sulaiman

16 papers receiving 1.7k citations

Hit Papers

The entry of nanoparticles into solid tumours1.3k20202026202220244008001.2k

Peers

Andrew Sulaiman
Comparison fields: 5 of 97
  • Biomaterials 723
  • Biomedical Engineering 873
  • Oncology 363
  • Molecular Biology 717
  • Immunology 205
Replace Jessica Ngai with:
Jessica Ngai United States
Da‐Yong Hou China
Wenqi Yu China
Fan Tong China
Suah Yang South Korea
Madduri Srinivasarao United States
Xin Lin China
Dayi Pan China
Zhiting Cao China
Huan Min China
Andrew Sulaiman relative to Jessica Ngai United States Jessica Ngai's profile →
Citations per field
00.5×2.9×
Jessica Ngai · 1×
Citations per year

Countries citing papers authored by Andrew Sulaiman

Since Specialization
Citations

This map shows the geographic impact of Andrew Sulaiman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Sulaiman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Sulaiman more than expected).

Fields of papers citing papers by Andrew Sulaiman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Sulaiman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Sulaiman. The network helps show where Andrew Sulaiman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Andrew Sulaiman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew Sulaiman Line = papers co-authored together Andrew Sulaiman links everyone, so they are left out of the graph.

All Works

18 of 18 papers shown
#Work
1 20250
2 20240
3 20247
4 20225
5 202135
6 202117
7
The entry of nanoparticles into solid tumoursbreakdown →
20201293
8 20204
9 202012
10 201921
11 201931
12 201837
13 201860
14 201777
15 201726
16 201740
17 201628
18 19899

About Andrew Sulaiman

Andrew Sulaiman is a scholar working on Oncology, Cell Biology and Biotechnology, having authored 18 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (9 papers), Hippo pathway signaling and YAP/TAZ (4 papers), Cancer-related Molecular Pathways (3 papers), Cancer Research and Treatments (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Immunotherapy and Immune Responses (2 papers), Wnt/β-catenin signaling in development and cancer (2 papers) and Nanoplatforms for cancer theranostics (2 papers). The work is most often cited by research in Biomaterials (723 citations), Biomedical Engineering (873 citations) and Oncology (363 citations). Andrew Sulaiman has collaborated with scholars based in Canada, United States and China. Frequent co-authors include Suresh Gadde, Presley MacMillan, Stefan Wilhelm, Anton Zilman, Zachary P. Lin, Shrey Sindhwani, Jessica Ngai, Netra U. Rajesh, Mikala Egeblad and Abdullah M. Syed. Their work appears in journals such as Nature Materials, FEBS Letters and International Journal of Molecular Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026